212Bismuth Linked to an Antipancreatic Carcinoma Antibody: Model for Alpha-Particle-Emitter Radioimmunotherapy
- 18 May 1988
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 80 (6), 449-452
- https://doi.org/10.1093/jnci/80.6.449
Abstract
For comparison of cytotoxicity from alpha-particle irradiation with that from conventional x-irradiation, 212Bi, an alpha-emitting ra-dionuclide, was attached to a monoclonal antibody that recognizes a cell surface antigen on human pancreatic carcinoma cells. For a given level of survival, the 212Bi-antibodyThis publication has 6 references indexed in Scilit:
- NEW METHOD FOR THE CHELATION OF IN-111 TO MONOCLONAL-ANTIBODIES - BIODISTRIBUTION AND IMAGING OF ATHYMIC MICE BEARING HUMAN-COLON CARCINOMA XENOGRAFTS1987
- Gastrointestinal Carcinoma-Associated Antigen Defined by a Murine Monoclonal AntibodyJNCI Journal of the National Cancer Institute, 1986
- Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy.Proceedings of the National Academy of Sciences, 1986
- Properties of Liposomes Containing 212PbInternational Journal of Nuclear Medicine and Biology, 1983
- Tumor Imaging with Radioactive Metal Chelates Conjugated to Monoclonal AntibodiesScience, 1982
- Astatine-211—Tellurium Radiocolloid Cures Experimental Malignant AscitesScience, 1981